LUNG
BEARISH
$1.44
Live
Pulmonx Corporation · NASDAQ
Target $5.17
(+258.8%)
$1.13
52W Range
$5.49
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$60.82M
P/E
N/A
ROE
-77.2%
Profit margin
-59.7%
Debt/Equity
1.04
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Pulmonx Corporation (LUNG) presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive earnings. While the company maintains strong short-term liquidity (Current Ratio 5.07) and impressive gross margins (74.19%), these are offset by negative revenue growth (-4.90%) and severe long-term price erosion (-96.7% over 5 years). The stark divergence between the analyst target price ($5.17) and the bearish insider activity suggests a speculative environment where fundamental deterioration outweighs theoretical upside.
Key Strengths
Strong liquidity position with a Current Ratio of 5.07
High Gross Margin of 74.19% indicating strong product value
Consistent track record of beating quarterly EPS estimates
Low Price-to-Sales ratio (0.67) suggesting potential undervaluation of revenue
Stable Piotroski F-Score (4/9) preventing immediate health collapse
Key Risks
Negative revenue growth (-4.90% YoY) indicating market share or demand issues
Deeply negative profit margins (-59.67%) and ROE (-77.19%)
Aggressive insider selling across C-suite (CEO, CTO, General Counsel)
Severe long-term capital destruction (-73.4% 1Y, -96.7% 5Y)
Micro-cap volatility and lack of positive cash flow data
AI Fair Value Estimate
Based on comprehensive analysis
$2.15
+49.3% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
45
30
10
55
0
AI Verdict
Speculative / High Risk
Key drivers: Negative revenue growth, Consistent insider selling, Severe historical price decline, Strong liquidity buffer
Confidence
90%
Value
45/100
Trades at a low multiple of sales, but lacks the earnings to support a traditional valuation.
Positives
- P/S ratio of 0.67 is low
- P/B ratio of 1.11 is near book value
Watchpoints
- No Graham Number due to negative earnings
- Negative P/E
Future
30/100
Growth metrics are contradictory; EPS is improving (less negative), but top-line revenue is shrinking.
Positives
- Positive EPS growth trend (YoY +24.2%)
Watchpoints
- Negative YoY revenue growth
- Negative Q/Q revenue growth
Past
10/100
Catastrophic historical price performance.
Positives
- Consistent EPS beats
Watchpoints
- 5-year return of -96.7%
- 1-year return of -73.4%
Health
55/100
Liquidity is the only strong pillar of the balance sheet.
Positives
- Current Ratio 5.07
- Quick Ratio 4.11
- Piotroski Score 4/9
Watchpoints
- Debt/Equity of 1.04
- Negative ROA/ROE
Dividend
0/100
Non-dividend paying growth/speculative stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.44
Analyst Target
$5.17
Upside/Downside
+258.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LUNG and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LUNG
Pulmonx Corporation
Primary
|
-96.7% | -86.8% | -73.4% | -9.4% | -14.3% | +5.9% |
|
MDAI
Spectral AI, Inc.
Peer
|
-81.1% | -87.0% | +48.0% | -16.3% | +40.1% | +11.4% |
|
ICCC
ImmuCell Corporation
Peer
|
-21.2% | +44.8% | +39.6% | +4.1% | +6.5% | +9.9% |
|
ATHE
Alterity Therapeutics Limited
Peer
|
-80.8% | -8.5% | +6.3% | -45.8% | +14.5% | +2.9% |
|
DCGO
DocGo Inc.
Peer
|
-94.3% | -93.1% | -77.6% | -55.1% | -15.2% | -9.4% |
LUN
Pulmonx Corporation
Primary
5Y
-96.7%
3Y
-86.8%
1Y
-73.4%
6M
-9.4%
1M
-14.3%
1W
+5.9%
MDA
Spectral AI, Inc.
Peer
5Y
-81.1%
3Y
-87.0%
1Y
+48.0%
6M
-16.3%
1M
+40.1%
1W
+11.4%
ICC
ImmuCell Corporation
Peer
5Y
-21.2%
3Y
+44.8%
1Y
+39.6%
6M
+4.1%
1M
+6.5%
1W
+9.9%
ATH
Alterity Therapeutics Limited
Peer
5Y
-80.8%
3Y
-8.5%
1Y
+6.3%
6M
-45.8%
1M
+14.5%
1W
+2.9%
DCG
DocGo Inc.
Peer
5Y
-94.3%
3Y
-93.1%
1Y
-77.6%
6M
-55.1%
1M
-15.2%
1W
-9.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.43
PEG Ratio
N/A
P/B Ratio
1.11
P/S Ratio
0.67
EV/Revenue
0.52
EV/EBITDA
-0.9
Market Cap
$60.82M
Profitability
Profit margins and return metrics
Profit Margin
-59.67%
Operating Margin
-43.82%
Gross Margin
74.19%
ROE
-77.19%
ROA
-22.96%
Growth
Revenue and earnings growth rates
Revenue Growth
-4.9%
Earnings Growth
N/A
Q/Q Revenue Growth
-4.91%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.04
Moderate
Current Ratio
5.07
Strong
Quick Ratio
4.11
Excellent
Cash/Share
$1.65
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
77.6%
Op. Margin
-43.8%
Net Margin
-46.1%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
1.39x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-03-04
$-0.25
+35.1% surprise
2025-11-12
$-0.34
+18.7% surprise
2025-07-30
$-0.38
+5.4% surprise
Healthcare Sector Comparison
Comparing LUNG against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-77.19%
This Stock
vs
-86.0%
Sector Avg
-10.2%
(Below Avg)
Profit Margin
-59.67%
This Stock
vs
-11.76%
Sector Avg
+407.5%
(Superior)
Debt to Equity
1.04
This Stock
vs
3.51
Sector Avg
-70.3%
(Less Debt)
Revenue Growth
-4.9%
This Stock
vs
90.15%
Sector Avg
-105.4%
(Slower)
Current Ratio
5.07
This Stock
vs
3.67
Sector Avg
+38.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LUNG
Pulmonx Corporation
|
BEARISH | $60.82M | - | -77.2% | -59.7% | $1.44 | |
|
MDAI
Spectral AI, Inc.
|
BEARISH | $58.87M | - | -% | -38.5% | $1.85 | Compare |
|
ICCC
ImmuCell Corporation
|
BEARISH | $64.01M | - | -3.8% | -3.8% | $7.08 | Compare |
|
ATHE
Alterity Therapeutics Limited
|
BEARISH | $64.35M | - | -43.2% | -223.3% | $3.55 | Compare |
|
DCGO
DocGo Inc.
|
BEARISH | $56.28M | - | -89.0% | -56.6% | $0.57 | Compare |
LUNG
Pulmonx Corporation
BEARISH
Mkt Cap
$61M
P/E
-
ROE
-77.2%
Price
$1.44
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | FRENCH GLENDON E III | Chief Executive Officer | Sale | 67,813 | $96,973 |
| 2026-03-02 | LEHMAN DAVID AARON | General Counsel | Stock Award | 150,000 | - |
| 2026-03-02 | LEHMAN DAVID AARON | General Counsel | Sale | 12,237 | $17,499 |
| 2026-03-02 | ROSE GEOFFREY BERAN | Officer | Stock Award | 100,000 | - |
| 2026-03-02 | ROSE GEOFFREY BERAN | Officer | Sale | 7,732 | $11,057 |
| 2026-03-02 | RADHAKRISHNAN SRIKANTH | Chief Technology Officer | Stock Award | 175,000 | - |
| 2026-03-02 | RADHAKRISHNAN SRIKANTH | Chief Technology Officer | Sale | 10,483 | $14,991 |
| 2025-12-08 | FLORIN DANIEL P | Director | Sale | 23,321 | $46,409 |
| 2025-12-01 | FRENCH GLENDON E III | Chief Executive Officer | Stock Award | 1,200,000 | - |
| 2025-12-01 | FRENCH GLENDON E III | Chief Executive Officer | Sale | 8,805 | $13,824 |
| 2025-12-01 | LEHMAN DAVID AARON | General Counsel | Sale | 10,278 | $16,136 |
| 2025-12-01 | SUNG DERRICK | Chief Operating Officer | Stock Award | 1,200,000 | - |
| 2025-12-01 | ROSE GEOFFREY BERAN | Officer | Sale | 6,322 | $9,926 |
FRENCH GLENDON E III
Chief Executive Officer
2026-03-02
67,813 shares
·
$96,973
LEHMAN DAVID AARON
General Counsel
2026-03-02
150,000 shares
LEHMAN DAVID AARON
General Counsel
2026-03-02
12,237 shares
·
$17,499
ROSE GEOFFREY BERAN
Officer
2026-03-02
100,000 shares
ROSE GEOFFREY BERAN
Officer
2026-03-02
7,732 shares
·
$11,057
RADHAKRISHNAN SRIKANTH
Chief Technology Officer
2026-03-02
175,000 shares
RADHAKRISHNAN SRIKANTH
Chief Technology Officer
2026-03-02
10,483 shares
·
$14,991
FLORIN DANIEL P
Director
2025-12-08
23,321 shares
·
$46,409
FRENCH GLENDON E III
Chief Executive Officer
2025-12-01
1,200,000 shares
FRENCH GLENDON E III
Chief Executive Officer
2025-12-01
8,805 shares
·
$13,824
LEHMAN DAVID AARON
General Counsel
2025-12-01
10,278 shares
·
$16,136
SUNG DERRICK
Chief Operating Officer
2025-12-01
1,200,000 shares
ROSE GEOFFREY BERAN
Officer
2025-12-01
6,322 shares
·
$9,926
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Canaccord Genuity
2026-03-05
Buy
Buy
D. Boral Capital
2026-03-05
Buy
Buy
D. Boral Capital
2026-02-20
Buy
Buy
D. Boral Capital
2025-11-13
Buy
Buy
Lake Street
2025-10-28
Buy
Buy
D. Boral Capital
2025-10-28
Buy
Buy
Past News Coverage
Recent headlines mentioning LUNG from our newsroom.
Newest → oldest
No matching news yet.